Julia Bonavitacola

Panelists at SLEEP 2023 presented preliminary data on how sleep interventions could close the gap in treating Black children and families in sleep health.

Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients.

A panel at SLEEP 2023 discussed the ways that long COVID-19 has affected numerous areas of sleep health.

Posters presented at SLEEP 2023 estimated the prevalence of idiopathic hypersomnia as well as incidence of comorbidities.

Presenters at SLEEP 2023 revealed research that linked childhood sleep patterns to weight in young children.

The sharp reduction in costs for hospitalization from respiratory syncytial virus (RSV) in infants 3 months and younger after the COVID-19 pandemic outweighed the cost increase for children aged 3 to 24 months.

Mark Fendrick, MD, speaks about how how minority populations may be the most at risk following the Braidwood ruling on preventive care.

Children were hospitalized most commonly due to respiratory syncytial virus (RSV) compared with influenza and COVID-19 during a season with respiratory pathogen cocirculation.

The SLEEP 2023 conference will be held in Indianapolis from June 3 to June 7 and promises to feature topics including sleep health disparities, hypersomnia, geriatric medicine, and new technologies.

Adalimumab had a slight advantage over infliximab in terms of adverse events when used to treat patients with noninfectious uveitis (NIU).

Nicholas Bagley, JD, professor at Michigan Law at the University of Michigan, speaks about the benefits of ongoing communication about the effects of the Braidwood ruling and what will be done to keep preventive care accessible.

Although lack of routine testing and limitations to current diagnostic testing likely lead to underreporting of respiratory syncytial virus, RSV still poses a substantial economic burden.

About 69% of pediatric patients had discontinued amblyopia therapy during COVID-19 even as their parents reported that adherence was good.

Nicholas Bagley, JD, professor at Michigan Law at the University of Michigan, discusses how Congress can help address the consequences of Braidwood v Becerra.

Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar.

A recent study compared hospitalizations and ages of children with respiratory syncytial virus (RSV) infection before the pandemic and afterwards.

Nicholas Bagley, JD, says immediate effects of the ruling have been modest so far.

An analysis of an urban population of children indicated that age was a strong predictor in the diagnosis of respiratory syncytial virus (RSV) and influenza.

The relationship between myopia and primary open-angle glaucoma (POAG) was stronger in Asian, Black, and Hispanic individuals compared with White individuals.

A study found that not being infected with respiratory syncytial virus (RSV) in the first year of life was associated with a decreased risk of developing asthma in childhood.

Cost sharing for several treatments could disappear following the Braidwood v Becerra ruling, according to A. Mark Fendrick, MD, director of the V-BID Center at the University of Michigan and co-editor in chief of The American Journal of Managed Care®.

A vaccine for adults 60 years and older was approved by the FDA for protection against respiratory syncytial virus, making it the first such vaccine to be approved worldwide.

Further epidemiologic studies on nonpharmaceutical interventions are warranted to assess their relationship with respiratory syncytial virus (RSV).

When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.

Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.

A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.

Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.

A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan, discusses how the Braidwood ruling can affect the efficacy of preventive care.

In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).

Researchers found that eyeglasses with traditional steps of 0.25D were less effective and less preferred by participants compared with those refracted in 0.05D steps.